Silence Therapeutics (SLN) Net Cash Flow (2024 - 2026)

Silence Therapeutics has disclosed Net Cash Flow across 3 years of filings, most recently posting -$5.6 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$5.6 million, up 90.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$59.2 million (up 24.3% YoY), and the FY2025 annual result was -$110.2 million, down 310.07% from the prior year.
• Net Cash Flow came in at -$5.6 million for Q1 2026 at Silence Therapeutics, up from -$70.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $74.0 million in Q1 2024 to a low of -$70.6 million in Q4 2025.
• The 3-year median for Net Cash Flow is -$5.6 million (2026), against an average of -$7.0 million.
• Peak annual rise in Net Cash Flow reached 172.4% in 2025, while the deepest fall reached 448.13% in 2025.
• Silence Therapeutics' Net Cash Flow stood at $38.5 million in 2024, then tumbled by 283.18% to -$70.6 million in 2025, then soared by 92.07% to -$5.6 million in 2026.
• The last three Net Cash Flow figures came in at -$5.6 million (Q1 2026), -$70.6 million (Q4 2025), and $40.4 million (Q3 2025), per Business Quant data.